Targeting Senescent Cells with Synthetic Biology
Lifespan.io (LEAF) - 09-Dec-2016CellAge is going to develop synthetic promoters which are specific to senescent cells, as promote...
Join the club for FREE to access the whole archive and other member benefits.
Postdoctoral researcher working on synthetic biology, gene therapy and ageing and CEO & Co-Founder of CellAge.
Mantas Matjusaitis is currently finishing his PhD in synthetic biology (University of Edinburgh, MRC Centre For Regenerative Medicine) and has been involved in the SENS Education programme. He holds a BSc in Biomedical Science, has worked for the global pharmaceutical company AstraZeneca and a number of scientific labs, with topics ranging from nanoparticles to stem cell identity. For the last two years, Mantas was also leading a team of scientists when he was a Vice President and then a President of Innovation Forum Edinburgh branch, an international organization aiming to facilitate collaboration between academics, industry and policy makers.
Visit website: https://www.crunchbase.com/person/mantas-matjusaitis
See also: CellAge - working with the aim to develop synthetic promoters that would be able to specifically identify senescent cells
Details last updated 04-Sep-2020
CellAge is going to develop synthetic promoters which are specific to senescent cells, as promote...